Grufity logoGrufity logo

WST

223.77USD-0.41(-0.18%)Market Closedas of 29 Nov 2022, 09:36 am

West Pharmaceutical Services Inc

Market Summary

USD223.77-0.41Market Closedas of 29 Nov 2022, 09:36 am
-0.18%

WST Stock Price

RSI Chart

Valuation

Market Cap

16.7B

Price/Earnings

26.46

Price/Sales

5.74

Price/Cashflow

25.52

MarketCap/EBT

22.76

Price/Sales

Profitability

EBT Margin

25.20%

Return on Equity

25.52%

Return on Assets

19.01%

Fundamentals

Revenue

Revenue (TTM)

2.9B

Revenue Y/Y

-2.77%

Revenue Q/Q

-10.94%

Earnings

Earnings (TTM)

630.6M

Earnings Y/Y

-31.32%

Earnings Q/Q

-36.02%

Price Action

52 Week Range

206.19474.77
(Low)(High)

Last 7 days

-0.5%

Last 30 days

-0.6%

Last 90 days

-24.4%

Trailing 12 Months

-48.9%

Financial Health

Current Ratio

3.8

Debt/Equity

0.08

Debt/Cashflow

3.12

Investor Care

Dividend Yield

0.32%

Dividend/Share (TTM)

0.72

Buy Backs (1Y)

0.06%

Diluted EPS (TTM)

8.25

Peers (Alternatives to West Pharmaceutical Services)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.3B
31.3B
3.72% -19.18%
27.1
5.87
11.35% 14.95%
174.5B
45.0B
5.93% -14.87%
20.4
3.83
6.43% 8.90%
115.4B
31.1B
-12.31% -30.06%
22.17
3.71
-1.67% 34.08%
30.3B
3.3B
9.83% -34.14%
45.68
9.17
6.53% -11.52%
16.7B
2.9B
-0.59% -48.90%
26.46
5.74
8.50% 2.96%
MID-CAP
6.4B
806.4M
16.86% -20.83%
-331.15
7.96
20.10% -221.96%
5.2B
664.2M
-19.30% 118.32%
160.13
7.81
76.53% 218.01%
3.7B
2.3B
-4.42% -41.41%
3.27
1.42
24.87% 6.11%
SMALL-CAP
1.4B
527.2M
16.07% -63.00%
29.31
2.69
12.53% -20.65%
1.4B
233.4M
-36.31% -72.28%
-4.82
6.12
8.78% -318.40%
1.4B
333.0M
-1.34% 55.18%
32.26
4.08
4.76% -40.54%
765.9M
259.0M
-14.55% -64.62%
-43.31
2.97
3.62% -967.02%
44.3M
7.9M
-18.95% -84.08%
-1.23
5.93
23.02% -7.81%
17.5M
37.6M
-84.83% -99.08%
-0.13
0.46
1.85% -22.51%

Financials for West Pharmaceutical Services

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.7%2,9092,9292,8812,8322,681
Gross Profit-1.7%1,1751,1951,1891,1761,086
  S&GA Expenses-7.2%329355366363341
  R&D Expenses0.9%5656555352
Earnings Before Taxes-5.8%733778762749682
Net Income-8.0%631686684662613
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.3%3,3173,3623,2953,3143,143
  Current Assets-2.1%1,7341,7711,6911,7421,598
    Cash Equivalents1.5%729719668763688
  Inventory0.4%413412417378354
  Net PPE-0.8%1,0691,0771,0661,0581,007
  Goodwill-2.4%104107109110109
Liabilities-9.7%846937969978940
  Current Liabilities-19.2%457565585594559
  Long Term Debt-16.9%209252253253254
    LT Debt, Current-95.0%244444444
    LT Debt, Non Current-0.3%207208208209210
Shareholder's Equity1.9%2,4712,4242,3262,3352,202
  Retained Earnings4.3%2,9132,7932,6172,4572,336
  Additional Paid-In Capital2.4%231225220249251
Accumulated Depreciation-0.4%1,1641,1691,1711,1581,140
Shares Outstanding0%7474747474
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-3.1%654675647584572
  Share Based Compensation-16.4%2732373834
Cashflow From Investing2.2%-270.80-277.00-266.90-253.10-233.30
Cashflow From Financing-31.4%-290.30-220.90-184.40-168.10-170.60
  Dividend Payments1.0%52525150
  Buy Backs15.5%203176147137137

Risks

What is the probability of a big loss on WST?

51.5%


Probability that West Pharmaceutical Services stock will be more than 20% underwater in next one year

11.9%


Probability that West Pharmaceutical Services stock will be more than 30% underwater in next one year.

4.2%


Probability that West Pharmaceutical Services stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does WST drawdown profile look like?

Y-axis is the maximum loss one would have experienced if West Pharmaceutical Services was unfortunately bought at previous high price.

Returns

Cumulative Returns on WST

24.3%


10-Year Cumulative Returns

20.4%


7-Year Cumulative Returns

17.9%


5-Year Cumulative Returns

15.3%


3-Year Cumulative Returns

What are the long-term rolling returns for WST?

FIve years rolling returns for West Pharmaceutical Services.

Which funds bought or sold WST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
3.43
-163,000
868,000
0.04%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-35.21
-121,620
136,000
0.08%
2022-11-22
CVA Family Office, LLC
-
-
-10,000
11,000
-%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,670,000
1,670,000
0.02%
2022-11-22
B. Riley Wealth Advisors, Inc.
REDUCED
-10.38
-84,000
228,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-7,331,000
30,020,000
0.05%
2022-11-21
FourThought Financial, LLC
-
-
4,000
28,000
-%
2022-11-21
Integrated Investment Consultants, LLC
-
-
-55,000
237,000
0.09%
2022-11-21
Sunbelt Securities, Inc.
-
-
-216,000
-
-%
2022-11-18
National Pension Service
ADDED
1.97
-4,797,000
26,639,000
0.06%

1–10 of 46

Latest Funds Activity

Are funds buying WST calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own WST

West Pharmaceutical Services News

ETF Daily News

O Shaughnessy Asset Management LLC Sells 409 Shares of West Pharmaceutical Services, Inc. (NYSE:WST).28 hours ago

WST Fair Value

Recent SEC filings of West Pharmaceutical Services

View All Filings
Date Filed Form Type Document
Nov 01, 2022
4
Insider Trading
Oct 27, 2022
8-K
Current Report
Oct 27, 2022
10-Q
Quarterly Report
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for WST

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-31
Winters Chad
SOLD FOR TAXES
-10,599
225.51
-47
VP, CAO & Corporate Controller
2022-08-02
Birkett Bernard
SOLD
-4,836,070
341.193
-14,174
Sr VP, CFO & COO
2022-08-01
Lockhart Stephen H
ACQUIRED
-
-
454
-
2022-08-01
Abraham Silji
SOLD
-1,848,310
343.935
-5,374
Chief Digital & Trans Officer
2022-06-21
Birkett Bernard
SOLD (Taxes)
-272,949
288.53
-946
Sr VP, CFO & COO
2022-05-24
FRIEL ROBERT F
ACQUIRED
-
-
632
-
2022-05-24
Keller Deborah L
ACQUIRED
-
-
632
-
2022-05-24
BUTHMAN MARK A
ACQUIRED
-
-
632
-
2022-05-24
Joseph Molly
ACQUIRED
-
-
632
-
2022-05-24
Michels Douglas A
ACQUIRED
-
-
632
-

1–10 of 50

Eric M. Green
10100
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

WST Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net sales$ 686.9$ 706.5$ 2,178.2$ 2,100.8
Cost of goods and services sold418.9418.31,304.11,225.6
Gross profit268.0288.2874.1875.2
Research and development13.613.142.639.1
Selling, general and administrative expenses66.391.9231.2264.8
Other (income) expense (Note 15)1.91.8(4.0)3.0
Operating profit186.2181.4604.3568.3
Interest expense2.21.86.25.6
Interest income(1.5)(0.4)(2.2)(0.7)
Other nonoperating expense (income)49.3(1.1)49.1(3.6)
Income before income taxes136.2181.1551.2567.0
Income tax expense20.412.085.873.0
Equity in net income of affiliated companies(4.8)(6.5)(17.5)(20.1)
Net income$ 120.6$ 175.6$ 482.9$ 514.1
Net income per share:    
Basic (in dollars per share)$ 1.62$ 2.37$ 6.49$ 6.95
Diluted (in dollars per share)$ 1.59$ 2.31$ 6.36$ 6.78
Weighted average shares outstanding:    
Basic (in shares)74.474.174.474.0
Diluted (in shares)75.776.075.975.8

WST Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 729.0$ 762.6
Accounts receivable, net485.3489.0
Inventories413.1378.4
Other current assets106.2112.0
Total current assets1,733.61,742.0
Property, plant and equipment2,232.92,215.0
Less: accumulated depreciation and amortization1,163.91,157.5
Property, plant and equipment, net1,069.01,057.5
Operating lease right-of-use assets86.669.3
Investments in affiliated companies188.6207.7
Goodwill104.0109.9
Intangible assets, net18.123.0
Deferred income taxes63.048.5
Pension and other postretirement benefits1.216.7
Other noncurrent assets52.739.2
Total Assets3,316.83,313.8
Current liabilities:  
Notes payable and other current debt2.244.2
Accounts payable188.9232.2
Pension and other postretirement benefits2.32.4
Accrued salaries, wages and benefits66.7116.3
Income taxes payable29.926.3
Operating lease liabilities13.39.3
Other current liabilities153.4163.4
Total current liabilities456.7594.1
Long-term debt207.2208.8
Deferred income taxes16.64.9
Pension and other postretirement benefits35.240.5
Operating lease liabilities77.263.0
Deferred compensation benefits19.228.9
Other long-term liabilities33.938.2
Total Liabilities846.0978.4
Commitments and contingencies (Note 17)
Equity:  
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding0.00.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.2 million, respectively18.818.8
Capital in excess of par value230.6249.0
Retained earnings2,913.12,456.7
Accumulated other comprehensive loss(308.5)(159.6)
Treasury stock, at cost (1.3 million and 1.1 million shares, respectively)(383.2)(229.5)
Total Equity2,470.82,335.4
Total Liabilities and Equity$ 3,316.8$ 3,313.8